Riyi Shi is a medical scientist specializing in uncovering the mechanisms of central nervous system trauma and diseases and instituting new treatments through innovative experimentation and pioneering new strategies in the field. His research contributions includes originating the use of double sucrose gap technique for recording action potential conduction, establishing the methods of neuronal membrane resealing by polyethelyne glycol (PEG), and identifying acrolein as a key pathological factor in spinal cord injury and multiple sclerosis. His research interests also include using nanotechnology to improve drug delivery to nervous tissue and incorporating biomedical engineering principles to enhance neuronal repair and diagnosis. This includes designing innovative scaffolds to enhance neuronal regeneration and using bioadhesives for neuronal tissue repair.
A neurotoxin called acrolein found in tobacco smoke that is thought to increase pain in people with spinal cord injury has now been shown to accumulate in mice exposed to the equivalent of 12 cigarettes daily over a short time period.
One implication is that if acrolein is exacerbating pain its concentration in the body could be reduced using the drug hydralazine, which has been approved by the U.S. Food and Drug Administration for hypertension, said Riyi Shi (pronounced Ree Shee), a professor in Purdue University's Department of Basic Medical Sciences, College of Veterinary Medicine, and Weldon School of Biomedical Engineering.
Dr. Riyi Shi
Neuroscience and Biomedical Engineering
Department of Basic Medical Sciences
Center for Paralysis Research
College of Veterinary Medicine
Weldon School of Biomedical Engineering